BUDGET IMPACT OF INTRODUCING ERDAFITINIB FOR PREVIOUSLY TREATED FGFR3-ALTERED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA IN GREECE
Author(s)
Maria Koulentaki, MSc1, Stylianos Ravanidis, PhD1, Danai Kourmpani, MSc2, Georgia Kourlaba, PhD3.
1Econcare LP, Athens, Greece, 2Johnson & Johnson Innovative Medicine, Athens, Greece, 3Department of Nursing, National and Kapodistrian University of Athens, Athens, Greece.
1Econcare LP, Athens, Greece, 2Johnson & Johnson Innovative Medicine, Athens, Greece, 3Department of Nursing, National and Kapodistrian University of Athens, Athens, Greece.
OBJECTIVES: To estimate the budget impact of introducing erdafitinib for adults with previously treated locally advanced or metastatic urothelial carcinoma (LA/mUC) whose tumours have susceptible FGFR3 genetic alterations in Greece.
METHODS: A budget impact model was developed to compare two scenarios: a current treatment mix without erdafitinib and a future treatment mix including erdafitinib. The analysis was conducted over a 5-year time horizon from a Greek payer perspective, with costs expressed in 2026 euros (€). The eligible population was estimated using Greek epidemiological inputs. Annual per-patient costs were derived from the cost-effectiveness model and reflected time on treatment, progression-free survival and progressed disease. Included costs comprised drug acquisition and administration, monitoring/resource use, adverse events, subsequent treatment, FGFR testing and end-of-life care. Unit costs were inflated to the 2026 costing year where required. Outputs included the annual eligible population, patients estimated to receive erdafitinib, annual costs and cumulative net budget impact.
RESULTS: The total eligible population was estimated at 40 patients in year 1 (Y1), decreasing slightly to 39 patients by year 5 (Y5). Of these, the number of patients estimated to receive erdafitinib increased from 10 (Y1) to 23 (Y5), reflecting gradual uptake over the 5-year horizon. Total annual costs without erdafitinib ranged from €723,020 (Y1) to €891,733 (Y5), while costs with erdafitinib ranged from €1,079,181 (Y1) to €1,864,332 (Y5). The annual net budget impact increased from €356,161 in Y1 to €972,599 in Y5. Over 5 years, cumulative costs were €4,280,305 without erdafitinib and €7,899,450 with erdafitinib, resulting in a cumulative net budget impact of €3,619,145.
CONCLUSIONS: Introducing erdafitinib in Greece is estimated to result in a moderate and predictable budget impact over 5 years, reflecting the small biomarker-defined eligible population and gradual treatment uptake. The average annual budget impact was estimated at €723,829, indicating a manageable financial impact on the Greek healthcare system.
METHODS: A budget impact model was developed to compare two scenarios: a current treatment mix without erdafitinib and a future treatment mix including erdafitinib. The analysis was conducted over a 5-year time horizon from a Greek payer perspective, with costs expressed in 2026 euros (€). The eligible population was estimated using Greek epidemiological inputs. Annual per-patient costs were derived from the cost-effectiveness model and reflected time on treatment, progression-free survival and progressed disease. Included costs comprised drug acquisition and administration, monitoring/resource use, adverse events, subsequent treatment, FGFR testing and end-of-life care. Unit costs were inflated to the 2026 costing year where required. Outputs included the annual eligible population, patients estimated to receive erdafitinib, annual costs and cumulative net budget impact.
RESULTS: The total eligible population was estimated at 40 patients in year 1 (Y1), decreasing slightly to 39 patients by year 5 (Y5). Of these, the number of patients estimated to receive erdafitinib increased from 10 (Y1) to 23 (Y5), reflecting gradual uptake over the 5-year horizon. Total annual costs without erdafitinib ranged from €723,020 (Y1) to €891,733 (Y5), while costs with erdafitinib ranged from €1,079,181 (Y1) to €1,864,332 (Y5). The annual net budget impact increased from €356,161 in Y1 to €972,599 in Y5. Over 5 years, cumulative costs were €4,280,305 without erdafitinib and €7,899,450 with erdafitinib, resulting in a cumulative net budget impact of €3,619,145.
CONCLUSIONS: Introducing erdafitinib in Greece is estimated to result in a moderate and predictable budget impact over 5 years, reflecting the small biomarker-defined eligible population and gradual treatment uptake. The average annual budget impact was estimated at €723,829, indicating a manageable financial impact on the Greek healthcare system.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
HTA96
Topic
Economic Evaluation, Epidemiology & Public Health, Health Technology Assessment
Disease
Oncology